Triptolide induces the cell apoptosis of osteosarcoma cells through the TRAIL pathway

Area of Science:

• * Pharmacology and Toxicology
• * Cancer Biology
• * Molecular Oncology

Background:

• * Triptolide is a diterpenoid epoxide from Tripterygium wilfordii (Thunder God Vine).
• * Previous research explored triptolide's pharmacology, pharmacokinetics, toxicology, and clinical applications.
• * Osteosarcoma is a primary bone cancer with limited effective treatments.

Purpose of the Study:

• * To investigate the effects of triptolide on osteosarcoma cell apoptosis.
• * To evaluate the anti-proliferative activity of triptolide in osteosarcoma.
• * To elucidate the molecular mechanisms underlying triptolide's anticancer effects.

Main Methods:

• * MG-63 osteosarcoma cells were treated with varying doses of triptolide (50, 100, 200 nM) or DMSO for 6, 12, and 24 hours.
• * Cell viability was assessed using MTT assay.
• * Apoptosis was detected by flow cytometry.
• * Caspase activity assays (caspase-3, -8, -9) and Western blot analysis were performed.
• * Signaling pathways including DR-5/p53/Bax/caspase-9/caspase-3 and DR-5/FADD/caspase-8/lysosomal/cathepsin B/caspase-3 were investigated.

Main Results:

• * Triptolide significantly suppressed MG-63 cell viability.
• * Triptolide treatment induced apoptosis in osteosarcoma cells.
• * The anticancer effects were linked to the activation of the DR-5/p53/Bax/caspase-9/caspase-3 pathway.
• * Triptolide also activated the DR-5/FADD/caspase-8/lysosomal/cathepsin B/caspase-3 pathway.
• * TRAIL-DR-5 played a crucial role in triptolide's anti-osteosarcoma activity.

Conclusions:

• * Triptolide demonstrates significant anti-proliferative and pro-apoptotic effects on osteosarcoma cells.
• * Triptolide's mechanism involves the activation of TRAIL-DR-5-mediated signaling pathways.
• * Triptolide shows promise as a potential novel chemotherapeutic agent for osteosarcoma treatment.